Interpace Diagnostics Group, a company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management, reported that the company has launched a new version of their AccuCEA product called “Insights” for Gastroenterologists who focus on diagnosing and treating pancreatic cancer.
The new AccuCEA Insights service provides physicians for whom the company has already provided first line testing, with additional information on how those results compare to those of other patients in the company’s proprietary database of over 15,000 patients, thus reporting incremental and valuable information on the patient’s potential molecular profile and overall risk for developing pancreatic cancer. When the report is delivered to the ordering physician, they have an opportunity to speak with one of the company’s expert molecular pathologists and discuss the potential benefits of conducting a full, molecular pathology review using PancraGen, the company’s fully integrated product that considers all the results from first line testing, imaging, cytology, and molecular testing and stratifies the patient in one of 4 risk categories.
Interpace Diagnostics, who has offered their AccuCEA product to customers for over 5 years, will continue to offer AccuCEA in addition to AccuCEA Insights. The primary benefit of the AccuCEA product vs. traditional carcinoembryonic antigen or CEA testing available from other labs is that AccuCEA is the only CEA assay that has been validated on small (200uL) amounts of cyst fluid. Interpace currently performs over 6,000 AccuCEA tests per year for their customers. CEA is a blood fluid chemistry test that is commonly done as part of an initial screening performed on patients suspected of having pancreatic and other types of cancer. This test, along with other common fluid chemistry tests like Amylase, may also be referred to as “first line testing”.
“The additional information provided via AccuCEA Insights provides physicians a more expansive view of their patient’s status and enables them to make an informed decision regarding the most appropriate next steps,” said Interpace President and CEO Jack Stover. “We believe customers who currently order first line testing services only will see the value in not only the incremental information provided via AccuCEAInsights but the full benefits of our fully integrated molecular product, PancraGEN.”